| SynOx Therapeutics–SEVERAL: investment, 202011 financing round Series A €37m co-led by HealthCap + Medicxi with Forbion + Gimv |
2020-11-19 |
| Lead Pharma–LifeSpring: public relations, 202011 service existent by LifeSpring Communications |
2020-11-16 |
| Roche–Lead Pharma: small-molecule immuno modulators, 202011– collab + license agreem up to €260m incl €10m upfront plus royalties |
2020-11-16 |
| Jeito Capital–Sanofi: investment, 202011 investment €50m by Sanofi |
2020-11-13 |
| Handl Therapeutics–UCB: investment, 202011 acquisition of Handl Therapeutics by UCB |
2020-11-12 |
| m2p-labs–Danaher: investment, 202011 acquisition of m2p-biolabs by Beckman Coulter Life Sciences |
2020-11-12 |
| Metagenomi–Agent Capital: investment, 202011 financing round Series A totalling $65m incl co-investor Agent Capital |
2020-11-12 |
| Metagenomi–Bayer: investment, 202011 financing round Series A totalling $65m incl co-lead investor Leaps by Bayer |
2020-11-12 |
| Metagenomi–HOF Capital: investment, 202011 financing round Series A totalling $65m incl co-investor HOF Capital |
2020-11-12 |
| Metagenomi–Humboldt Fund: investment, 202011 financing round Series A totalling $65m incl co-lead investor Humboldt Fund |
2020-11-12 |
| Metagenomi–InCube Ventures: investment, 202011 financing round Series A totalling $65m incl co-investor InCube Ventures |
2020-11-12 |
| Metagenomi–SEVERAL: investment, 202011 financing round Series A $65m co-led by Leaps by Bayer + Humboldt Fund |
2020-11-12 |
| Metagenomi–Sozo Ventures: investment, 202011 financing round Series A totalling $65m incl co-investor Sozo Ventures |
2020-11-12 |
| Synendos Therapeutics–SEVERAL: investment, 202011 financing round Series A CHF20m co-led by Kurma Partners + Sunstone LSV |
2020-11-12 |
| MorphoSys–Cherry Biolabs: Hemibody technology, 202011– license €na to apply Hemibody technology to six exclusive targets |
2020-11-11 |
| Catalym–Bavaria (govt): investment, 202011 financing round Series B totalling €50m incl co-investor Wachstumsfonds Bayern |
2020-11-10 |
| Catalym–Germany (govt): investment, 202011 financing round Series B totalling €50m incl co-investor Coparion |
2020-11-10 |
| Catalym–Novartis: investment, 202011 financing round Series B totalling €50m incl co-investor Novartis Venture Fund |
2020-11-10 |
| Catalym–SEVERAL: investment, 202011 financing round Series B €50m led by Vesalius Biocapital III |
2020-11-10 |
| Catalym–Vesalius Biocapital: investment, 202011 financing round Series B totalling €50m incl lead investor Vesalius Biocapital III |
2020-11-10 |
| Apeiron–Domainex: drug discovery services, 202011– collab expansion supply of lead optimisation services for Cbl-b targeting APN431 compound series |
2020-11-09 |
| Congenica–Cambridge Innovation Capital: investment, 202011 financing round Series C totalling £39m incl existing + co-investor CIC |
2020-11-09 |
| Congenica–Consilium: public relations, 202011 service existent by CSC |
2020-11-09 |
| Congenica–Downing Ventures: investment, 202011 financing round Series C totalling £39m incl existing + co-investor Downing |
2020-11-09 |
| Congenica–IDO Investments: investment, 202011 financing round Series C totalling £39m incl new + co-investor IDO Investments |
2020-11-09 |
| Congenica–Lazard: financial services, 202011 supply service Lazard is financial advisor with regard to £39m Series C financing round |
2020-11-09 |
| Congenica–Legal & General: investment, 202011 financing round Series C totalling £39m incl new + co-lead investor Legal & General |
2020-11-09 |
| Congenica–Parkwalk Advisors: investment, 202011 financing round Series C totalling £39m incl existing + co-investor Parkwalk |
2020-11-09 |
| Congenica–Puhua Capital: investment, 202011 financing round Series C totalling £39m incl new + co-investor Puhua Capital |
2020-11-09 |
| Congenica–SEVERAL: investment, 202011 financing round Series C £39m ($50m) co-led by Tencent + Legal & General |
2020-11-09 |
| Congenica–Tencent: investment, 202011 financing round Series C totalling £39m incl new + co-lead investor Tencent |
2020-11-09 |
| Congenica–Xeraya: investment, 202011 financing round Series C totalling £39m incl new + co-investor Xeraya |
2020-11-09 |
| Oxford Biomedica–PhoreMost: GCT discovery, 202011– collab €na using Siteseeker to find targets for CAR-T cell therapies using LentiVector technology |
2020-11-09 |
| Stargazer Pharmaceuticals–SEVERAL: investment, 202011 financing round Series A $57m with Novo Holdings + venBio + Canaan Partners + Pontifax + FFB |
2020-11-09 |
| Vera Therapeutics–Merck (DE): atacicept, 202011– license for 10% equity in Vera + €605m milestones + royalties |
2020-11-09 |
| Vera Therapeutics–Merck (DE): investment, 202011 Merck reveices 10% equity in Vera Tx as part of license deal for atacicept |
2020-11-09 |
| Emisphere–Novo Group: investment, 202011– acquisition of Emisphere by Novo Nordisk for $1.35b in cash on a cash/debt-free basis |
2020-11-06 |
| Cytek Biosciences–SEVERAL: investment, 202011 financing round Series D $120m co-led by RA Capital + Hillhouse Capital |
2020-11-05 |
| Galapagos–OncoArendi: chitinase inhibitors, 202011– collab + license ww developm + commerc OATD-01 €25m+€2m upfront + €295m milestones + royalties |
2020-11-05 |
| Memo Therapeutics–Bernina BioInvest: investment, 202011 financing round Series B totalling CHF14m incl new + co-investor Bernina BioInvest |
2020-11-05 |
| Memo Therapeutics–Halsin Partners: public relations, 202011 service existent by Halsin Partners |
2020-11-05 |
| Memo Therapeutics–Jaquet Partners: investment, 202011 financing round Series B totalling CHF14m incl existing + co-investor Jaquet Partners |
2020-11-05 |
| Memo Therapeutics–OTHER: investment, 202011 financing round Series B totalling CHF14m incl new private investors |
2020-11-05 |
| Memo Therapeutics–Redalpine: investment, 202011 financing round Series B totalling CHF14m incl existing + co-investor Redalpine |
2020-11-05 |
| Memo Therapeutics–Schroders: investment, 202011 financing round Series B totalling CHF14m incl existing + co-investor Schroder Adveq |
2020-11-05 |
| Memo Therapeutics–SEVERAL: investment, 202011 financing round Series B CHF14m led by Swisscanto by ZKB |
2020-11-05 |
| Memo Therapeutics–Verve Capital Partners: investment, 202011 financing round Series B totalling CHF14m incl existing + co-investor Investiere |
2020-11-05 |
| Memo Therapeutics–Zürcher Kantonalbank: investment, 202011 financing round Series B totalling CHF14m incl existing + lead investor Swisscanto by ZKB |
2020-11-05 |
| VelosBio–Merck (US): investment, 202011– acquisition $2.75b in cash of VelosBio by Merck |
2020-11-05 |
| The Protein Brewery–SEVERAL: investment, 202011 financing round Series A €22m led by Novo Holdings |
2020-11-03 |
| Corlieve Therapeutics–SEVERAL: investment, 202011 seed financing round from Kurma Partners + Idinvest Partners + Pureos Bioventures |
2020-11-02 |
| Fountain Healthcare Partners–Kyowa Kirin: investment, 202011 final closing of Fund III totalling addit €7m incl new investor Kyowa Kirin Co Ltd |
2020-11-02 |
| Fountain Healthcare Partners–SEVERAL: investment, 202011 final closing of Fund III addit €7m incl Kyowa Kirin bringing total fund to hard cap of €125m |
2020-11-02 |
| Horizon Discovery–PerkinElmer: investment, 202011– cash tender offer £296m ($383m) representing total enterprise value of £284m ($368m) |
2020-11-02 |
| Kiadis–Sanofi: investment, 202011– cash tender offer €308m for Kiadis Pharma NV at €5.45 per share (272% premium over closing price on 30 Oct) |
2020-11-02 |
| Mainstay Medical–Fountain Healthcare Partners: investment, 202011 existent investment of Fountain HP Fund III |
2020-11-02 |
| Oxford BioDynamics–Instinctif Partners: public relations, 202011 service existent by Instinctif |
2020-11-02 |
| Monocl–Definitive Healthcare: investment, 202010 acquisition of Monocl by Definitive Healthcare LLC |
2020-10-29 |
| Galecto–LifeSci: public relations, 202010 supply service existent media contact LifeSci Advisors |
2020-10-28 |
| Galecto–SEVERAL: investment, 202010 US IPO $85m+12.75m with 5.67m+850k common stock shares at $15/share |
2020-10-28 |
| Eagle Genomics–ETF Partners: investment, 202010 financing round totalling $9m incl investor Environmental Technologies Fund (ETF) |
2020-10-27 |
| Eagle Genomics–Granpool Innovative Investments: investment, 202010 financing round totalling $9m incl investor consortium led by Granpool |
2020-10-27 |
| Eagle Genomics–Sarum PR: public relations, 202010 service existent Sarum PR is press contact |
2020-10-27 |
| Eagle Genomics–SEVERAL: investment, 202010 financing round $9m with ETF Partners + investor consortium led by Granpool II |
2020-10-27 |
| Kaffe Bueno–Denmark (govt): investment, 202010 seed financing round totalling €1.1m incl investor Vaekstfonden |
2020-10-27 |
| Kaffe Bueno–OTHER: investment, 202010 seed financing round totalling €1.1m incl a Danish business angel as investor |
2020-10-27 |
| Kaffe Bueno–Paulig Group: investment, 202010 seed financing round totalling €1.1m incl investor PINC |
2020-10-27 |
| Kaffe Bueno–SEVERAL: investment, 202010 seed financing round €1.1m from PINC + Vaekstfonden + The Yield Lab + a Danish business angel |
2020-10-27 |
| Kaffe Bueno–Yield Lab: investment, 202010 seed financing round totalling €1.1m incl investor The Yield Lab IE |
2020-10-27 |
| Prokarium–Flerie Invest: investment, 202010 financing round Series B totalling $21m incl co-investor Flerie Invest (FF) |
2020-10-27 |
| Prokarium–Korea Investment Partners: investment, 202010 financing round Series B totalling $21m led by KIP |
2020-10-27 |
| Prokarium–Riyadh Valley Company: investment, 202010 financing round Series B totalling $21m incl co-investor RVC (FF) |
2020-10-27 |
| Prokarium–SEVERAL: investment, 202010 financing round Series B $21m led by Korea Investment Partners |
2020-10-27 |
| Prokarium–United Kingdom (govt): investment, 202010 financing round Series B totalling $21m incl co-investor UK Future Fund (FF) |
2020-10-27 |
| TVM–Lilly: investment, 202010 final closing totalling $478m of fund TVM Life Science Innovation II incl investor Eli Lilly |
2020-10-27 |
| TVM–OCP Capital: investment banking, –202010 supply service OCP supports fund raising for $478m TMV LSI II fund |
2020-10-27 |
| TVM–SEVERAL: investment, 202010 final closing of $478m of fund TVM Life Science Innovation II incl Eli Lilly |
2020-10-27 |
| Unilever–Eagle Genomics: microbiomics, <202010 collab use of e[datascientist] platform to support claims for enzyme-containing Zendium toothpaste |
2020-10-27 |
| AskBio–Bayer: investment, 202010 acquisition by Bayer for $2b upfront plus $2b milestones |
2020-10-26 |
| Base Genomics–Bristows: legal services, 202010 supply Bristows LLP legal advisor to Base Genomics for acquisition by Exact Sciences |
2020-10-26 |
| Base Genomics–Exact Sciences: investment, 202010 acquisition 100% of Base Genomics Ltd for $410m in cash (net of cash + certain other adjustments) |
2020-10-26 |
| Base Genomics–William Blair: financial services, 202010 supply William Blair financial advisor to Base Genomics for acquisition by Exact Sciences |
2020-10-26 |
| Eternygen–SEVERAL: investment, 202010 financing round Series A2 1st closing €5m led by Evotec |
2020-10-26 |
| Exact Sciences–K&L Gates: legal services, 202010 supply legal advisor to Exact Escience for acquisitions of Base Genomics + Thrive Earlier |
2020-10-26 |
| Exact Sciences–XMS Capital: financial services, 202010 supply financial advisor to Exact Escience for acquisitions of Base Genomics + Thrive Earlier |
2020-10-26 |
| MD Biosciences–MLM Medical Labs: investment, 202010 acquisition of MD Biosciences Inc by MLM Medical Labs |
2020-10-26 |
| Scorpion Therapeutics–Abingworth: investment, 202010 financing round Series A totalling $108m incl co-investor Abingworth |
2020-10-26 |
| Scorpion Therapeutics–SEVERAL: investment, 202010 financing round Series A $108m led by Atlas Venture + Omega Funds + Vida Ventures |
2020-10-26 |
| Thrive Earlier Detection–Exact Sciences: investment, 202010– acquisition $1.7b upfront with 35% in cash + 65% common stock plus $450m milestones |
2020-10-26 |
| Cara Therapeutics–Vifor Pharma: investment, 202010 equity investment $50m in connection with US license agreement for Korsuva |
2020-10-20 |
| Abcam–SEVERAL: investment, 202010 US IPO $156.5m+23.5m with 8.95m+1.34m ADSs at $17.5/ADS at Nasdaq Global Market |
2020-10-19 |
| Topas Therapeutics–BioMedPartners: investment, 202010 financing round Series B totalling €22m incl new + co-lead investor BioMedPartners |
2020-10-19 |
| Topas Therapeutics–Boehringer: investment, 202010 financing round Series B totalling €22m incl existing + co-investor BIVF |
2020-10-19 |
| Topas Therapeutics–EMBL: investment, 202010 financing round Series B totalling €22m incl existing + co-investor EMBL Ventures |
2020-10-19 |
| Topas Therapeutics–Epidarex Capital: investment, 202010 financing round Series B totalling €22m incl existing + co-investor Epidarex Capital |
2020-10-19 |
| Topas Therapeutics–Evotec: investment, 202010 financing round Series B totalling €22m incl existing + co-investor Evotec |
2020-10-19 |
| Topas Therapeutics–Gimv: investment, 202010 financing round Series B totalling €22m incl existing + co-investor Gimv |
2020-10-19 |
| Topas Therapeutics–SEVERAL: investment, 202010 financing round Series B €22m co-led by Vesalius + BIoMedPartners plus all existing investors |
2020-10-19 |
| Topas Therapeutics–Vesalius Biocapital: investment, 202010 financing round Series B totalling €22m incl new + co-lead investor Vesalius Biocapital III |
2020-10-19 |
| NovaBiotics–Powerscourt: public relations, 202010 service existent by Powerscourt |
2020-10-16 |
![[LSE] Life-Sciences-Europe.com - The European Life Sciences Web Portal](/images/basics/lse-life-sciences-europe-portal-logo-2019.png){kind=logo}
Date
![Picture [iito] Made Without Love 650x80px](/banner/iito-business-intelligence-20200507-650-080-summer-banner-series-made-without-love.jpg)
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
